Navigation Links
Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
Date:4/18/2008

Berlin, Germany: Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

Professor Michael Untch told the 6th European Breast Cancer Conference (EBCC-6) in Berlin today (Friday) that the women in the trial did not suffer from any serious side effects of the treatment such as severe heart problems. These results are very challenging, as both trastuzumab and anthracyclines are associated with cardiac toxicity.

Prof Untch said: When we started this trial it was considered very courageous to give patients anthracyclines plus trastuzumab, but we wanted to expose patients to trastuzumab for as long as possible before surgery to make it as effective as possible. To minimise the risk, we excluded patients with any previous heart problems and excluded patients with ejection fractions of below 55%. However, our results showed no increase in toxicity for the combination chemotherapy plus trastuzumab compared with chemotherapy alone. There were no cases of congestive heart failure or cardiac-related deaths, and other cardiac-related symptoms were not severe. The combination chemotherapy plus trastuzumab proved to be the most effective combination, but, at the same time, we have to keep an eye on the heart. Therefore, cardiac monitoring every three months is a must for patients treated with this regimen.

A total of 1510 breast cancer patients were recruited to the GeparQuattro trial between 2006-2007; 453 of them had tumours that over-expressed the HER2 receptor (a particularly aggressive form of the disease). Before surgery they received four cycles of epirubicin/cyclophosphamide (EC) and were then randomised to receive either four cycles of docetaxel (D) or four cycles of D-capecitabine (DX), or a combination of both D and DX, or four cycles of D followed by four cycles of DX. Women with HER2-positive tumours also received trastuzumab at the same time as the neoadjuvant chemotherapy, and then continued with it after surgery for up to one year. Both the chemotherapy and the trastuzumab were given via three-weekly infusions.

When they analysed the data 15 months after the start of the trial, the researchers found that there was no evidence of any cancer remaining in the breast in 41.3% of women with HER2-positive tumours who had received both chemotherapy and trastuzumab; whereas the pathologic complete response rate (pCR, complete disappearance of cancer cells from the breast) was 19.5% in women who had not received trastuzumab.

Prof Untch said: Previous studies have shown that HER2-positive women who do not receive trastuzumab never have a pCR rate that exceeds 20%. Our study has shown that it is possible to combine trastuzumab with anthracycline/taxane chemotherapy regimen without any significant adverse effects on the heart, thereby significantly increasing the pCR rates for these women to 41.3%.

The researchers are continuing to follow the women to see whether the pCR rates translate into improved overall survival. In addition, they have started a further trial, the GeparQuinto study, which will compare the combination of chemotherapy plus trastuzumab with lapatinib (a tyrosine kinase inhibitor) as a pre-operative treatment.

The GeparQuattro trial was run jointly in more then 100 breast cancer centres by the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynkologische Onkologie (AGO), the two major German cooperative research groups for the treatment of gynaecological malignancies and breast cancer. Professor Gunter von Minckwitz, managing director of GBG, is the principal investigator for the study.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Related biology news :

1. UC health news: molecular pathway may predict chemotherapy effectiveness
2. A search for protection against chemotherapy cardiotoxicity
3. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Exercise improves thinking, reduces diabetes risk in overweight children
6. Endobronchial valve significantly improves emphysema
7. Teamwork improves learning and career success
8. New clinical data shows chromium picolinate improves cognitive function
9. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
10. Key to out-of-control immune response in lung injury found
11. Flies can turn off their immune response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
(Date:3/9/2017)... , Australia , March 9, 2017 ... data at the prestigious World Lung Imaging Workshop at ... Andreas Fouras , was invited to deliver the latest ... medicine. This globally recognised event brings together leaders at ... the latest developments in lung imaging. ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... -- Personal Genome Diagnostics Inc. (PGDx) today announced that it ... Cancer Research (AACR) Annual Meeting 2017, being held April 1-5, ... also announced that five scientists associated with PGDx—two co-founders and ... AACR Team Science Award. ... Doug Ward , CEO of Personal ...
(Date:3/29/2017)... 29, 2017 QIAGEN N.V. (NASDAQ: QGEN ; ... U.S. launch of its ipsogen ® JAK2 RGQ PCR Kit ... Drug Administration as a qualitative in vitro diagnostic test for the detection of ... ... on QIAGEN,s Rotor-Gene ® Q MDx system, which is a member of ...
(Date:3/29/2017)... ... 29, 2017 , ... (March 29, 2017) — Nerium ... as an active member of the Mexican Direct Selling Association A.C. (AMVD ... in relationship marketing. This professional organization fosters loyal and fair competition among companies ...
(Date:3/29/2017)... CA (PRWEB) , ... March 29, 2017 , ... ... cutting edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy ... Today the company announced that its new round of awards are being ...
Breaking Biology Technology: